Clinical trial NCT05279248: The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
Official title: Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Human Papilloma Virus Infection Type 16
Human Papilloma Virus Infection Type 18
Measles
Rubella
Mumps
Keywords: Immunogenicity
Safety
Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli)
Measles Mumps and Rubella Combined Vaccine, Live
Lead sponsor: Zhejiang Provincial Center for Disease Control and Prevention
Sponsor class: OTHER_GOV
First posted: 2022-03-15
Enrollment: 300
Sex: FEMALE
Minimum age (years): 13
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles Mumps and Rubella Combined Vaccine, Live（MMR）

Detailed description: Main subjects:

To evaluate the immunogenicity of HPV vaccine and MMR vaccine at the same time but at different sites as not inferior to vaccination of HPV vaccine or MMR vaccine alone.

Secondary subjects:

To evaluate the safety of simultaneous administration of HPV vaccine and MMR vaccine.

Eligibility criteria: Inclusion Criteria:

1. Females aged between 13 and 14 years when they receive the first vaccination (13≤age\<15);
2. Participants aged 13-14 years whose legal guardian can provide identity certificate, or representative can provide authorization;
3. Judged as healthy and eligible for vaccination by the investigators through a self-reported medical history and some physical examinations;
4. Participants aged 13-14 years, able to sign or whose legal guardian agree to sign the written informed consent; or participants aged 18-26 years and agree to sign the written informed consent;
5. Able to comply with the requests of the study;
6. Axillary temperature not higher than 37.0°C; Nonpregnancy verified by a urine pregnancy test;

Exclusion Criteria:

1. Pregnant or lactating woman and any woman who are willing or intend to become pregnant in next 7 months;
2. Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the first vaccination, or plan to use during the study period;
3. Participants who received an immunosuppressive agent or other immunomodulator agent for a long term (for 14 days or more) within 6 months of the first vaccination, or systematic corticosteroid (however, a topical corticosteroid is allowed, such as ointment, eye drops, inhalant, or nasal spray);
4. Participants who received immunoglobulin and/or blood product 3 months prior to the first vaccination, or planned to receive during the study period;
5. Use of any inactivated vaccine 14 days preceding dosing of study vaccine or attenuated vaccine 21 days before the enrollment;
6. Participants had fever (auxiliary temperature ≥38.0 °C) within 3 days prior to vaccination, or any acute disease requiring systematic antibiotics or antiviral therapy within the past 5 days;
7. Concurrently participating another clinical trial;
8. Participants who have received HPV vaccines;
9. Participants with immunodeficiency disease (such as HIV positive), primary disease in vital organs, cancer (or precancerous lesion), or chronic history of immunological disease requiring treatment (including systemic lupus erythematosus), rheumatoid arthritis, asplenia or splenectomy due to any conditions, and other immunological diseases that may impact immune response as considered by investigator), etc.;
10. Participants with a history of allergy, including severe adverse reactions due to the past vaccination, such as hypersensitivity, urticaria, dyspnea, angioneurotic edema, or abdominal pain;
11. Participants with asthma, which is unstable in the past 2 years, requiring emergency treatment, hospitalization, or oral or intravenous corticosteroid;
12. Participants with concurrent severe medical disorders, such as hypertension, heart disease, diabetes mellitus, or hyperthyroidism, etc.;
13. Participants with coagulation dysfunction (such as coagulation factor deficiency, blood-clotting disorder, or platelet disorder) or coagulation disorders, as diagnosed by a physician;
14. Participants with epilepsy, excluding febrile epilepsy in patients under 2 years old, alcoholic epilepsy 3 years prior to alcohol abstinence, or pure epilepsy requiring no treatment within the past 3 years;
15. Participants who are not compliant to the study's requirements due to psychological conditions, or those with prior or existing mental disease or bipolar psychosis which are not well controlled within the past 2 years and require taking drugs, or those with suicidal tendency within the past 5 years;
16. According to the investigator's judgment, there might be some medical, psychological, social or occupational factors which might impact on the individual to obey the protocol or sign the informed consent;

Primary outcomes:
measure: Evaluate the seroconversion rates and geometric mean concentrations of anti-HPV 16 and 18 at Months 7 (type specific neutralizing antibody)
timeFrame: Specific neutralizing antibodies at 7 months after first dose
measure: Evaluate seroconversion rates and geometric mean concentrations of anti-measles at the 1st month after MMR vaccination
timeFrame: 1 months after vaccination
measure: Evaluate seroconversion rates and geometric mean concentrations of anti-rubella at the 1st month after MMR vaccination
timeFrame: 1 months after vaccination
measure: Evaluate seroconversion rates and geometric mean concentrations of anti-mumps at the 1st month after MMR vaccination
timeFrame: 1 months after vaccination
Secondary outcomes:
measure: Local and systematic adverse events/reactions occurred within 7 days after each vaccination
timeFrame: During the 7-day (Day 0-6) period following each vaccination
measure: Adverse events/reactions occurred within 30 days after each vaccination
timeFrame: Within 30 days (Day 0-30) after any vaccination
measure: Serious adverse events occurred throughout the study
timeFrame: Up to 7 months
Other outcomes:
Locations:
city: Shaoxing
country: China
facility: Yuecheng Center for Disease Control and Prevention
state: Zhejiang
city: Wuyi
country: China
facility: Wuyi Center for Disease Control and Prevention
state: Zhejiang
Study officials:
References: